Emjard-M XR
Generic Name
Empagliflozin and Metformin Hydrochloride Extended-Release Tablet
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emjard m xr 10 mg tablet | ৳ 30.00 | ৳ 120.00 |
Description
Overview of the medicine
Emjard-M XR is an oral antidiabetic drug used for the treatment of Type 2 Diabetes Mellitus, combining an SGLT2 inhibitor (Empagliflozin) and a Biguanide (Metformin XR) to improve glycemic control.
Uses & Indications
Dosage
Adults
Individualize the starting dose based on the patient’s current therapy, effectiveness, and tolerability. Typically, one tablet once daily in the morning with food. Do not exceed the maximum recommended daily dose.
Elderly
No specific dose adjustment is required based on age alone. However, renal function should be assessed more frequently, particularly in elderly patients with declining renal function.
Renal_impairment
Contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). Dose adjustment or discontinuation may be necessary for eGFR <45 mL/min/1.73 m².
How to Take
Take Emjard-M XR orally once daily with a meal to reduce gastrointestinal side effects. Swallow the tablet whole; do not crush, cut, or chew it.
Mechanism of Action
Empagliflozin inhibits SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics
Onset
Empagliflozin's glucose-lowering effect begins within hours. Metformin's full therapeutic effect is seen over several days.
Excretion
Empagliflozin is primarily excreted via urine (approximately 50%) and feces (approximately 50%). Metformin is primarily eliminated via renal excretion as unchanged drug.
Half life
Empagliflozin's plasma half-life is approximately 12.4 hours. Metformin's plasma half-life is approximately 4-9 hours, but the extended-release formulation prolongs its action.
Absorption
Empagliflozin is rapidly absorbed with peak plasma concentrations occurring 1.5 hours post-dose. Metformin XR is slowly absorbed, with peak concentrations typically between 4-7 hours.
Metabolism
Empagliflozin is primarily metabolized via glucuronidation. Metformin is excreted unchanged in the urine and undergoes minimal hepatic metabolism.
Side Effects
Contraindications
- •Hypersensitivity to empagliflozin, metformin, or any component of the formulation.
- •Severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or dialysis.
- •Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- •Acute conditions with the potential to alter renal function such as dehydration, severe infection, shock.
Drug Interactions
Alcohol
Increases the effect of metformin on lactate metabolism, increasing the risk of lactic acidosis.
Iodinated Contrast Agents
Metformin should be temporarily discontinued at the time of or prior to the imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m², in patients with a history of liver disease, alcoholism, or heart failure, or in patients who will be administered intra-arterial iodinated contrast. Metformin should be withheld for at least 48 hours after the procedure and reinstituted only after renal function has been re-evaluated and found to be stable.
Diuretics (e.g., loop or thiazide diuretics)
Increased risk of dehydration and hypotension with SGLT2 inhibitors. May also increase the risk of lactic acidosis with metformin.
Insulin and Insulin Secretagogues (e.g., Sulfonylureas)
Increased risk of hypoglycemia; a lower dose of insulin or insulin secretagogue may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, symptomatic and supportive treatment should be initiated. Empagliflozin is minimally dialyzable. Metformin is dialyzable; hemodialysis may be useful for removing accumulated metformin, particularly in cases of lactic acidosis.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. Avoid use during lactation as empagliflozin and metformin are excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented for specific formulation
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in